Prosecution Insights
Prosecution Insights
20 pending office actions • 12 art units • 18 examiners • 0 of 20 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (5%) |
| §103 only | 6 (30%) |
| §112 only | 3 (15%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 2 (10%) |
| Multi-statute (no §101) | 6 (30%) |
| No statute on record | 1 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CARTER, SANDRA DILLAHUNT | 2 | 56.1% | +29.7% |
| NGUYEN, QUANG | 2 | 38.1% | +53.0% |
| GRABER, JAMES J | 1 | 45.9% | +57.0% |
| REGA, KYLE THOMAS | 1 | 61.8% | +40.7% |
| STEPHENS, AMELIA CAROLE | 1 | 80.0% | +50.0% |
| DIBRINO, MARIANNE | 1 | 43.2% | +41.6% |
| HUDSON, AMY ROSE | 1 | 75.0% | +11.4% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| DRISCOLL, MAUREEN VARINA | 1 | 64.2% | +43.7% |
| BATES, KEENAN ALEXANDER | 1 | 44.8% | +76.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18043497 | COMPOSITIONS AND METHODS FOR TARGETING PLASMODIUM MALE GAMETE PROTEIN TO BLOCK MALARIA PARASITE TRANSMISSION | XIAO, YAN | 7d |
| 18265405 | ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS | STEPHENS, AMELIA CAROLE | 14d |
| 18012031 | METHODS AND COMPOSITIONS FOR EDITING THE B2M LOCUS IN B CELLS | HUDSON, AMY ROSE | 71d |
| 18441393 | ENGRAFTABLE CELL-BASED IMMUNOTHERAPY FOR LONG-TERM DELIVERY OF THERAPEUTIC PROTEINS | GRABER, JAMES J | — |
| 18554737 | ENGINEERING PEPTIDES FOR A A VB6 INTEGRIN BINDING AND RELATED METHODS OF USE AND SYNTHESIS | COFFA, SERGIO | — |
| 18546199 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | HOWARD, ZACHARY C | — |
| 18044752 | DIAGNOSTIC METHODS FOR KAWASAKI DISEASE | FRITCHMAN, REBECCA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18336276 | EXPRESSION OF FOXP3 IN EDITED CD34+ CELLS | NGUYEN, QUANG | 157d overdue |
| 17424140 | MICROENVIRONMENT SENSORS TO REGULATE ENGINEERED GENE EXPRESSION | BATES, KEENAN ALEXANDER | 147d overdue |
| 17586067 | METHODS OF USE FOR CAR T CELLS | DRISCOLL, MAUREEN VARINA | 139d overdue |
| 17931258 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | HUYNH, PHUONG N | 16d overdue |
| 18265405 | ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS | STEPHENS, AMELIA CAROLE | 14d |
| 18012031 | METHODS AND COMPOSITIONS FOR EDITING THE B2M LOCUS IN B CELLS | HUDSON, AMY ROSE | 71d |
| 18021450 | CONSTITUTIVELY ACTIVE TCF1 TO PROMOTE MEMORY-ASSOCIATED TRAITS IN CAR T CELLS | REGA, KYLE THOMAS | 76d |
| 18828243 | EARLY INTERVENTION METHODS TO PREVENT OR AMELIORATE TOXICITY | CARTER, SANDRA DILLAHUNT | — |
| Art Unit | Apps |
|---|---|
| 1631 | 4 |
| 1674 | 3 |
| 1636 | 2 |
| 1641 | 2 |
| 1644 | 2 |
| 1645 | 1 |
| 1658 | 1 |
| 2671 | 1 |
| 1758 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18828243 | EARLY INTERVENTION METHODS TO PREVENT OR AMELIORATE TOXICITY | CARTER, SANDRA DILLAHUNT | 1674 | §103 | Final Rejection | — | Pending | Sep 09, 2024 |
| 18441393 | ENGRAFTABLE CELL-BASED IMMUNOTHERAPY FOR LONG-TERM DELIVERY OF THERAPEUTIC PROTEINS | GRABER, JAMES J | 1631 | §102§112 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18021450 | CONSTITUTIVELY ACTIVE TCF1 TO PROMOTE MEMORY-ASSOCIATED TRAITS IN CAR T CELLS | REGA, KYLE THOMAS | 1636 | §103 | Non-Final OA | 76d | Pending | Aug 15, 2023 |
| 18336276 | EXPRESSION OF FOXP3 IN EDITED CD34+ CELLS | NGUYEN, QUANG | 1631 | §103DP | Non-Final OA | 157d overdue | Pending | Jun 16, 2023 |
| 18265405 | ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS | STEPHENS, AMELIA CAROLE | 1645 | §102§103§112Other | Non-Final OA | 14d | Pending | Jun 05, 2023 |
| 18189433 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | DIBRINO, MARIANNE | 1641 | §112Other | Non-Final OA | — | Pending | Mar 24, 2023 |
| 18012031 | METHODS AND COMPOSITIONS FOR EDITING THE B2M LOCUS IN B CELLS | HUDSON, AMY ROSE | 1636 | §102§103 | Final Rejection | 71d | Pending | Dec 21, 2022 |
| 17931258 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | HUYNH, PHUONG N | 1641 | DP | Final Rejection | 16d overdue | Pending | Sep 12, 2022 |
| 17586067 | METHODS OF USE FOR CAR T CELLS | DRISCOLL, MAUREEN VARINA | 1644 | §103§112DP | Non-Final OA | 139d overdue | Pending | Jan 27, 2022 |
| 17426041 | CHIMERIC CYTOKINE RECEPTORS | CARTER, SANDRA DILLAHUNT | 1674 | §112 | Non-Final OA | — | Pending | Jul 27, 2021 |
| 17424140 | MICROENVIRONMENT SENSORS TO REGULATE ENGINEERED GENE EXPRESSION | BATES, KEENAN ALEXANDER | 1631 | §103 | Final Rejection | 147d overdue | Pending | Jul 19, 2021 |
| 16605740 | OPTIMIZED LENTIVIRAL VECTOR FOR XLA GENE THERAPY | NGUYEN, QUANG | 1631 | §112 | Final Rejection | — | Pending | Oct 16, 2019 |
| 18554737 | ENGINEERING PEPTIDES FOR A A VB6 INTEGRIN BINDING AND RELATED METHODS OF USE AND SYNTHESIS | COFFA, SERGIO | 1658 | §102§112 | Final Rejection | — | Pending | Oct 10, 2023 |
| 18463683 | Processing Images to Associate with Stages of a Surgical Procedure | KUDO, KEN | 2671 | §103 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18546199 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | HOWARD, ZACHARY C | 1674 | §102§112 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18044752 | DIAGNOSTIC METHODS FOR KAWASAKI DISEASE | FRITCHMAN, REBECCA M | 1758 | §101 | Final Rejection | — | Pending | Mar 09, 2023 |
| 18043497 | COMPOSITIONS AND METHODS FOR TARGETING PLASMODIUM MALE GAMETE PROTEIN TO BLOCK MALARIA PARASITE TRANSMISSION | XIAO, YAN | 1642 | §102§112 | Non-Final OA | 7d | Pending | Feb 28, 2023 |
| 18042448 | SINGLE-DOMAIN ANTIBODIES THAT BIND SARS-COV-2 | BARRERA, IMMACULADA | 1671 | Other | Non-Final OA | 10d overdue | Pending | Feb 21, 2023 |
| 18059369 | MODIFIED HEMATOPOIETIC STEM/PROGENITOR AND NON-T EFFECTOR CELLS, AND USES THEREOF | BELYAVSKYI, MICHAIL A | 1644 | §103Other | Final Rejection | 7d | Pending | Nov 28, 2022 |
| 17705082 | RESUSCITATION DOSING KIT | ZIEGLER, MATTHEW D | 3785 | §103 | Non-Final OA | 154d overdue | Pending | Mar 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial